Initiating Buprenorphine for Chronic Pain Management

Patient Selection and Pre-Initiation Assessment

The American College of Physicians recommends screening for depression before initiating any long-term opioid therapy using a two-question screen followed by PHQ-9 if positive, with scores ≥10 requiring psychiatric referral before proceeding 1
The National Kidney Foundation suggests assessing renal function carefully, as buprenorphine is safer than morphine, codeine, or tramadol in renal impairment, though dose adjustments and frequent monitoring are still required 2, 3
The American Society of Addiction Medicine recommends collaborating with palliative care, pain, and/or substance use disorder specialists when managing patients with substance use disorder to optimize pain management 2, 3
The American Psychiatric Association suggests reassuring patients that addiction history will not prevent adequate pain management, as this reduces anxiety and improves treatment adherence 4, 5

The American Pain Society recommends minimum dose increases of 25%-50% when titrating buprenorphine, though patient factors like frailty, comorbidities, and organ function must guide dosing changes 2, 3

The American Academy of Pain Medicine advises against abruptly stopping full agonist opioids and immediately starting buprenorphine, as buprenorphine's high μ-receptor binding affinity will displace other opioids and precipitate severe withdrawal 4, 5, 6
The Journal of Clinical Oncology suggests prescribing immediate-release opioids at 5%-20% of the total daily morphine equivalent dose for breakthrough pain episodes 2, 3

The National Comprehensive Cancer Network recommends continuing NSAIDs or other non-opioid analgesics if they provide additional benefit and are not contraindicated 2, 3
The American Society of Clinical Oncology suggests writing continuous scheduled dosing orders rather than PRN orders to maintain consistent analgesia 4, 5

The National Institute of Diabetes and Digestive and Kidney Diseases states that buprenorphine is primarily excreted fecally, making it safer than morphine, codeine, meperidine, or tramadol in renal impairment 2, 3
The American College of Clinical Pharmacy recommends performing more frequent clinical observation and dose adjustments in patients with renal or hepatic impairment 2, 3

The American Society of Health-System Pharmacists notes that buprenorphine demonstrates a ceiling effect on respiratory depression, making it significantly safer than hydromorphone, fentanyl, or other full agonists 1
The Institute for Safe Medication Practices suggests proactively offering education and strategies to prevent adverse effects and monitoring for their development 2, 3